Mesoblast Option to Issue up to US$50m Convertible Notes
Filed with ASX · · 3 pages · English
Story so far
Earlier from Mesoblast
- Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes
- MSB Annual Financial Results and Operational Update
- Annual Financial Results Presentation
- Preliminary Final Report including Appendix 4E
- Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®
Later from Mesoblast
- Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences
- Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs
- Ryoncil® Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access
- Ryoncil® Revenues Increase 66% in Second Quarter Post Launch
- Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast